PCA3 score vs PSA free/total accuracy in prostate cancer diagnosis at repeat saturation biopsy

Anticancer Research

Volumn 31, Issue 12, 2011, Pages 4445-4449

  Pepe, Pietro ^a   Aragona, Francesco ^a  

^a CANNIZZARO HOSPITAL   (Italy)

Author keywords

Cancer diagnosis; PCA3; Prostate cancer; PSA free total; Repeat biopsy; Saturation prostate biopsy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER DIAGNOSIS; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DIAGNOSTIC TEST ACCURACY STUDY; DIGITAL RECTAL EXAMINATION; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE CANCER GENE 3 SCORE; REPEAT SATURATION PROSTATE BIOPSY;

AGED; ANTIGENS, NEOPLASM; AREA UNDER CURVE; BIOPSY; HUMANS; MALE; MEDICAL ONCOLOGY; MIDDLE AGED; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; ROC CURVE;

EID: 84855170451     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Määttänen L, Bangma CH, Aus G, Villers A, Rebillard X, van der Kwast T, Blijenberg BG, Moss SM, de Koning HJ and Auvinen A: Screening of prostate cancer mortality in randomized European study. N Engl Med 360: 1320-1328, 2009.
2. Pepe P and Aragona F: Saturation prostate needle biopsy and prostate cancer detection at initial and repeat evaluation. Urology 70: 1131-1135, 2007. (Pubitemid 350297372)
3. Walz J, Graefen M, Chun FK, Erbersdobler A, Haese A, Steuber T, Schlomm T, Huland H and Karakiewicz PI: High incidence of prostate cancer detected by saturation biopsy after previous negative biopsy series. Eur Urol 50: 498-505, 2006. (Pubitemid 44189057)
4. Marks LS, Fradet Y, Deras IL, Blase A, Mathis J, Aubin SM, Cancio AT, Desaulniers M, Ellis WJ, Rittenhouse H and Groskopf J: PCA3 molecular urinary assay for prostate cancer in men undergoing repeat biopsy. Urology 69: 532-535, 2007. (Pubitemid 46428401)
5. Haese A, de la Taille A, van Poppel H, Marberger M, Stenzl A, Mulders PF, Huland H, Abbou CC, Remzi M, Tinzl M, Feyerabend S, Stillebroer AB, van Gils MP and Schalken JA: Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol 54: 1081-1088, 2008.
6. Perdonà S, Cavadas V, Di Lorenzo G, Damiano R, Chiappetta G, Del Prete P, Franco R, Azzarito G, Scala S, Arra C, De Sio M and Autorino R: Prostate cancer detection in the "grey area" of prostate-specific antigen below 10 ng/ml: head-to head comparison of the update PCPT calculator and Chun's nomogram, two risk estimators incorporating prostate cancer antigen 3. Eur Urol 59: 81-87, 2011.
7. Bostwick DG, Grignon DJ, Hammond ME, Amin MB, Cohen M, Crawford D, Gospadarowicz M, Kaplan RS, Miller DS, Montironi R, Pajak TF, Pollack A, Srigley JR and Yarbro JW: Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 124: 995-1000, 2000. (Pubitemid 30602040)
8. Epstein J, Walsh P and Carmichael M: Pathological and clinical findings to predict tumor extent of non palpable (stage T1c) prostate cancer. JAMA 271: 368-374, 1994. (Pubitemid 24037911)
9. Catalona W, Smith D and Ornstein D: Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4 ng/ml and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA 277: 1452-1455, 1994. (Pubitemid 27208887)
10. Hoffman R, Clanon D, Littenberg B, Frank JJ and Peirce JC: Using free-to-total PSA ratio to detect prostate cancer in men with non specific elevations of PSA levels. J Gen Intern Med 15: 739-748, 2000.
11. Pepe P and Aragona F: Incidence of insignificant prostate cancer using free/total PSA: results of a case-finding protocol on 14453 patients. Prostate Cancer Prostatic Dis 13: 316-19, 2010.
12. Groskopf J, Aubin SM, Deras IL, Blase A, Bodrug S, Clark C, Brentano S, Mathis J, Pham J, Meyer T, Cass M, Hodge P, Macairan ML, Marks LS and Rittenhouse H: APTIMA molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem 52: 1089-1095, 2006. (Pubitemid 43794421)
13. Vlaemink-Guillem V, Ruffion A, Andrè J, Devonec M and Paparel P: Urinary prostate cancer 3 test: toward the age of reason? Urology 75: 447-453, 2010.
14. Deras IL, Aubin SM, Blasé A Day JR, Koo S, Partin AW, Ellis WJ, Marks LS, Fradet Y, Rittenhouse H and Groskopf J: PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol 179: 1587-1592, 2008.
15. Aubin SM, Reid J, Sarno MJ Blase A, Aussie J, Rittenhouse H, Rittmaster R, Andriole GL and Groskopf J: PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of dutasteride REDUCE trial. J Urol 184: 1947-1952, 2010.
16. Auprich M, Chun FK, Ward JF, Pummer K, Babaian R, Augustin H, Luger F, Gutschi S, Budäus L, Fisch M, Huland H, Graefen M and Haese A: Critical assessment of preoperative urinary prostate cancer antigen 3 on the accuracy of prostate cancer staging. Eur Urol 59: 96-105, 2011.
17. Fradet Y, Saad F, Aprikian A, Dessureault J, Elhilali M, Trudel C, Mâsse B, Piché L and Chypre C: uPM3, a new molecular urine test for the detection of prostate cancer. Urology 64: 311-15, 2004.
18. Panebianco V, Sciarra A, DE Berardinis E, Busetto GM, Lisi D, Buonocore V, Gentile V, Di Silverio F and Passariello R: PCA3 urinary test versus 1H-MRSI and DCEMR in the detection of prostate cancer foci in patients with biochemical alterations. Anticancer Res 31: 1399-05, 2011.
19. Schilling D, Hennenlotter J, Munz M, Bökeler U, Sievert KD and Stenzl A: Interpretation of the prostate cancer 3 in reference to the individual clinical background: implication for daily practice. Urol Int 85: 159-65, 2010.
20. Vlaeminck-Guillem V, Campos-Fernandes JL, Champetier D, Chikh K, Decaussin-Petrucci M, Devonec M, Gobeaux N, Paparel P, Perrin P, Rodriguez-Lafrasse C and Ruffion A: Value of PCA3 urinary test for prostate biopsy decision: the Lyon-Sud university hospital experience. Ann Biol Clin 69: 31-39, 2011.
21. Ploussard G, Haese A, Van Poppel H, Marberger M, Stenzl A, Mulders PF, Huland H, Bastien L, Abbou CC, Remzi M, Tinzl M, Feyerabend S, Stillebroer AB, Van Gils MP, Schalken JA and de La Taille A: The prostate cancer gene 3 (PCA3) urine test in men with previous negative biopsies: does free-to-total prostate-specific antigen ratio influence the performance of the PCA3 score in predicting positive biopsies. BJU Int 106: 1143-1147, 2010.
22. Remzi M, Haese A, Van Poppel H, De La Taille A, Stenzl A, Hennenlotter J and Marberger M: Follow-up of men with an elevated PCA3 score and negative biopsy: does an elevated PCA3 score indeed predict the presence of prostate cancer? BJU Int 106: 1138-1142, 2010.
23. Roobol MJ, Schroder FH, van Leenders GL, Hessels D, van den Bergh RC, Wolters T and van Leeuwen PJ: Performance of prostate cancer antigen 3 (PCA3) and prostate-specific antigen in pre-screened men: reproducibility and detection characteristics for prostate cancer patients with high PCA3 score (>100). Eur Urol 58: 893-899, 2010.